Nitric	0	6	B-Gene_or_gene_product
oxide	7	12	I-Gene_or_gene_product
synthase	13	21	I-Gene_or_gene_product
inhibition	22	32	O
results	33	40	O
in	41	43	O
synergistic	44	55	O
anti	56	60	O
-	60	61	O
tumour	61	67	B-Pathological_formation
activity	68	76	O
with	77	81	O
melphalan	82	91	B-Drug_or_compound
and	92	95	O
tumour	96	102	B-Gene_or_gene_product
necrosis	103	111	I-Gene_or_gene_product
factor	112	118	I-Gene_or_gene_product
alpha	119	124	I-Gene_or_gene_product
-	124	125	O
based	125	130	O
isolated	131	139	O
limb	140	144	B-Organism_subdivision
perfusions	145	155	O
.	155	156	O

Nitric	158	164	B-Drug_or_compound
oxide	165	170	I-Drug_or_compound
(	171	172	O
NO	172	174	B-Drug_or_compound
)	174	175	O
is	176	178	O
an	179	181	O
important	182	191	O
molecule	192	200	O
in	201	203	O
regulating	204	214	O
tumour	215	221	B-Pathological_formation
blood	222	227	B-Organism_substance
flow	228	232	O
and	233	236	O
stimulating	237	248	O
tumour	249	255	B-Pathological_formation
angiogenesis	256	268	O
.	268	269	O

Inhibition	270	280	O
of	281	283	O
NO	284	286	B-Gene_or_gene_product
synthase	287	295	I-Gene_or_gene_product
by	296	298	O
L	299	300	B-Drug_or_compound
-	300	301	I-Drug_or_compound
NAME	301	305	I-Drug_or_compound
might	306	311	O
induce	312	318	O
an	319	321	O
anti	322	326	O
-	326	327	O
tumour	327	333	B-Pathological_formation
effect	334	340	O
by	341	343	O
limiting	344	352	O
nutrients	353	362	O
and	363	366	O
oxygen	367	373	B-Drug_or_compound
to	374	376	O
reach	377	382	O
tumour	383	389	B-Tissue
tissue	390	396	I-Tissue
or	397	399	O
affecting	400	409	O
vascular	410	418	B-Multi-tissue_structure
growth	419	425	O
.	425	426	O

The	427	430	O
anti	431	435	O
-	435	436	O
tumour	436	442	B-Pathological_formation
effect	443	449	O
of	450	452	O
L	453	454	B-Drug_or_compound
-	454	455	I-Drug_or_compound
NAME	455	459	I-Drug_or_compound
after	460	465	O
systemic	466	474	O
administration	475	489	O
was	490	493	O
studied	494	501	O
in	502	504	O
a	505	506	O
renal	507	512	B-Pathological_formation
subcapsular	513	524	I-Pathological_formation
CC531	525	530	I-Pathological_formation
adenocarcinoma	531	545	I-Pathological_formation
model	546	551	O
in	552	554	O
rats	555	559	B-Organism
.	559	560	O

Moreover	561	569	O
,	569	570	O
regional	571	579	O
administration	580	594	O
of	595	597	O
L	598	599	B-Drug_or_compound
-	599	600	I-Drug_or_compound
NAME	600	604	I-Drug_or_compound
,	604	605	O
in	606	608	O
combination	609	620	O
with	621	625	O
TNF	626	629	B-Gene_or_gene_product
and	630	633	O
melphalan	634	643	B-Drug_or_compound
,	643	644	O
was	645	648	O
studied	649	656	O
in	657	659	O
an	660	662	O
isolated	663	671	O
limb	672	676	B-Organism_subdivision
perfusion	677	686	O
(	687	688	O
ILP	688	691	O
)	691	692	O
model	693	698	O
using	699	704	O
BN175	705	710	B-Pathological_formation
soft	711	715	I-Pathological_formation
-	715	716	I-Pathological_formation
tissue	716	722	I-Pathological_formation
sarcomas	723	731	I-Pathological_formation
.	731	732	O

Systemic	733	741	O
treatment	742	751	O
with	752	756	O
L	757	758	B-Drug_or_compound
-	758	759	I-Drug_or_compound
NAME	759	763	I-Drug_or_compound
inhibited	764	773	O
growth	774	780	O
of	781	783	O
adenocarcinoma	784	798	B-Pathological_formation
significantly	799	812	O
but	813	816	O
was	817	820	O
accompanied	821	832	O
by	833	835	O
impaired	836	844	O
renal	845	850	B-Organ
function	851	859	O
.	859	860	O

In	861	863	O
ILP	864	867	O
,	867	868	O
reduced	869	876	O
tumour	877	883	B-Pathological_formation
growth	884	890	O
was	891	894	O
observed	895	903	O
when	904	908	O
L	909	910	B-Drug_or_compound
-	910	911	I-Drug_or_compound
NAME	911	915	I-Drug_or_compound
was	916	919	O
used	920	924	O
alone	925	930	O
.	930	931	O

In	932	934	O
combination	935	946	O
with	947	951	O
TNF	952	955	B-Gene_or_gene_product
or	956	958	O
melphalan	959	968	B-Drug_or_compound
,	968	969	O
L	970	971	B-Drug_or_compound
-	971	972	I-Drug_or_compound
NAME	972	976	I-Drug_or_compound
increased	977	986	O
response	987	995	O
rates	996	1001	O
significantly	1002	1015	O
compared	1016	1024	O
to	1025	1027	O
perfusions	1028	1038	O
without	1039	1046	O
L	1047	1048	B-Drug_or_compound
-	1048	1049	I-Drug_or_compound
NAME	1049	1053	I-Drug_or_compound
(	1054	1055	O
0	1055	1056	O
-	1056	1057	O
64	1057	1059	O
%	1059	1060	O
and	1061	1064	O
0	1065	1066	O
-	1066	1067	O
63	1067	1069	O
%	1069	1070	O
respectively	1071	1083	O
)	1083	1084	O
.	1084	1085	O

An	1086	1088	O
additional	1089	1099	O
anti	1100	1104	O
-	1104	1105	O
tumour	1105	1111	B-Pathological_formation
effect	1112	1118	O
was	1119	1122	O
demonstrated	1123	1135	O
when	1136	1140	O
L	1141	1142	B-Drug_or_compound
-	1142	1143	I-Drug_or_compound
NAME	1143	1147	I-Drug_or_compound
was	1148	1151	O
added	1152	1157	O
to	1158	1160	O
the	1161	1164	O
synergistic	1165	1176	O
combination	1177	1188	O
of	1189	1191	O
melphalan	1192	1201	B-Drug_or_compound
and	1202	1205	O
TNF	1206	1209	B-Gene_or_gene_product
(	1210	1211	O
responses	1211	1220	O
increased	1221	1230	O
from	1231	1235	O
70	1236	1238	O
to	1239	1241	O
100	1242	1245	O
%	1245	1246	O
)	1246	1247	O
.	1247	1248	O

Inhibition	1249	1259	O
of	1260	1262	O
NO	1263	1265	B-Gene_or_gene_product
synthase	1266	1274	I-Gene_or_gene_product
reduces	1275	1282	O
tumour	1283	1289	B-Pathological_formation
growth	1290	1296	O
both	1297	1301	O
after	1302	1307	O
systemic	1308	1316	O
and	1317	1320	O
regional	1321	1329	O
(	1330	1331	O
ILP	1331	1334	O
)	1334	1335	O
treatment	1336	1345	O
.	1345	1346	O

A	1347	1348	O
synergistic	1349	1360	O
anti	1361	1365	O
-	1365	1366	O
tumour	1366	1372	B-Pathological_formation
effect	1373	1379	O
of	1380	1382	O
L	1383	1384	B-Drug_or_compound
-	1384	1385	I-Drug_or_compound
NAME	1385	1389	I-Drug_or_compound
is	1390	1392	O
observed	1393	1401	O
in	1402	1404	O
combination	1405	1416	O
with	1417	1421	O
melphalan	1422	1431	B-Drug_or_compound
and	1432	1435	O
/	1435	1436	O
or	1436	1438	O
TNF	1439	1442	B-Gene_or_gene_product
using	1443	1448	O
ILP	1449	1452	O
.	1452	1453	O

These	1454	1459	O
results	1460	1467	O
indicate	1468	1476	O
a	1477	1478	O
possible	1479	1487	O
role	1488	1492	O
of	1493	1495	O
L	1496	1497	B-Drug_or_compound
-	1497	1498	I-Drug_or_compound
NAME	1498	1502	I-Drug_or_compound
for	1503	1506	O
the	1507	1510	O
treatment	1511	1520	O
of	1521	1523	O
solid	1524	1529	O
tumours	1530	1537	B-Pathological_formation
in	1538	1540	O
a	1541	1542	O
systemic	1543	1551	O
or	1552	1554	O
regional	1555	1563	O
setting	1564	1571	O
.	1571	1572	O

